Search Results - paul+erhardt

7 Results

Sort By:

Confederated C Prime Agents vs Cancers (PDAC) & Metabolic Disorders

Project ID: D2020-28 Background Based upon the success of a mixture of simvastatin (SIM) + metformin (Met) + digoxin (Dig), dubbed “C3”, for treating pancreatic ductal adenocarcinoma (PDAC) via a pleiotropic mechanism where attenuation of the BIRC5 pathway is a major component, we have pursued novel, single-molecular constructs that combine...

Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same

Novel PPARδ Agonists for Bone Growth Background Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone loss. There are...

Advancement in Platinum Based Cancer Therapeutics

Project ID: D2013-02 Background One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells. Although increased DNA repair has been shown to be a major mechanism of cancer drug resistance, not much was done until recently to address this challenge. The researchers at The University of Toledo have...

Compounds for non-lethal micropinocytosis and exosome production

Project ID: D2017-25 Background Exosomes are vesicles in the range of 30 to 120nm, which are released from mammalian cells when multi-vesicular endosomes fuse with the plasma membrane. In recent times, exosomes have been implicated in cancer. Mounting evidence suggests that exosomes play an important role in mediating intercellular communication...

Compounds for disrupting microtubule networks and mitosis in brain cancer

Project ID: D2014-42 Background Primary brain tumors and secondary intracranial tumors from metastatic spread of other cancers (e.g., melanoma, lung carcinoma) have been inaccessible to therapy with microtubule-targeted agents (vincristine, vinblastine, paclitaxel) because the latter do not readily cross the blood-brain barrier. Invention...

Cancer Therapy via Simultaneous Non-apoptotic Cell Death Mechanisms

Project ID: D2018-15 Background Most current cancer therapies rely on agents that trigger apoptotic (programmed) cell-death pathways. During treatment, tumors can acquire mutations that diminish apoptotic responses and become chemoresistant, often accompanied by increased drug efflux and enhanced DNA repair. This resistance contributes to therapeutic...

Advancement in Platinum Based Cancer Therapeutics

Project ID: D2014-33Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells....